YA-101

Multiple System Atrophy (MSA)

Phase 2Active

Key Facts

Indication

Multiple System Atrophy (MSA)

Phase

Phase 2

Status

Active

Company

AI‑powered biotech developing disease‑modifying CNS therapies, with a Phase‑II orphan drug candidate for Multiple System Atrophy.

Drug	Company	Phase	Status
HB-adMSCs for Multiple System Atrophy	Hope Biosciences	Phase 1/2	Active
Anti-alpha-synuclein program for MSA (acquired by AC Immune)	AFFiRiS	Phase 1	Acquired/Partnered
anle138b	Modag	Phase 1/2	Active
Novel Neuroscience Candidate	Teva Pharmaceutical Industries	Phase 2	Active
Anti-alpha-synuclein Oligomer mAb	BioArctic AB	Discovery	Research
ATH434	Alterity Therapeutics	Phase 2	Active, Recruiting